BY 244
Latest Information Update: 13 Oct 2004
At a glance
- Originator ALTANA Pharma
- Class
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 13 Oct 2004 No development reported - Preclinical for Respiratory tract disorders in Germany (PO)
- 05 Jul 2002 Byk Gulden is now called ALTANA Pharma
- 17 Feb 2000 Preclinical development for Respiratory tract disorders in Germany (PO)